¤E¤Q¤T¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- µÇŦ¬ì

(B) 1.45·³¤k¯f¤HªºµÇŦ¶W­µªiÀˬd¦p¹Ï67¡A¤U¦C¦³Ãö¦¹¯f¤Hªº±Ô­z¦óªÌ¤£¥¿½T¡H
A.¬ù¦³50%¯f¤H¦b60·³¥ª¥k·|¶i®i¬°¥½´ÁµÇ°IºÜ¡A¤@¨Ç¦MÀI¦]¤l¥]¬A¨k©Ê¡B30·³¤§«e¶EÂ_¦¹¯f¡B35·³¤§«eµo¥Í°ª¦åÀ£¡BPKD1°ò¦]«¬µ¥¡C
B.¥Ø«e¤wª¾¦³¨â­Ó°ò¦]©M¦¹¯f¦³Ãö¡A¨ä¤¤PKD1¸û¦h¡A¬ù¦û65%¡A¦ì¸m¦b²Ä¥|¹ï¬V¦âÅé¡A¨äÂàĶªº³J¥Õ½èºÙpolycystin 1¡A¥i¯à©MÂ÷¤l³q¹Dªº½Õ¸`¦³Ãö¡C
C.¬ù¦³¥|¦¨ªº¯f¤Hµo¥Í¦×²´¥i¨£¦å§¿¡A²Ä¤@¦¸¦å§¿­Yµo¥Í¦b30·³¤§«e¡A¹w«á¸û®t¡C±`¨£ªº­ì¦]¬OÅn¸~¥X¦å¡A¦ý¦å§¿±`¤£¶W¹L¤@¶g¡C
D.Æ`¤º¦åºÞ½Fµo¥Íªº¤ñ²v¬ù¦b5-10%¡A³q±`¦³®a±Ú¸s»E©Ê¡C¿zÀËÆ`¤º¦åºÞ½F¨Ã¤£»Ý­n¡C
E.³o¨Ç¯f¤H±µ¨üµÇŦ²¾´Óªº¹w«á¡A©M¨ä¥LµÇŦ¯e¯f±µ¨ü²¾´Ó¬Û·í¡A¥B²¾´Ó¤£¶·±N¦hÅnµÇºK°£¡A°£«DÅn¸~±`¨Öµo·P¬V©Î¥X¦å¡C
 
(E) 2.25·³¨k©Ê¦]¤UªÏ¤ô¸~¦í°|¡A¯f¤H¹L¥h¥v¨ÃµL¯S®í¡C¦í°|Àˬd¦åÀ£¬°140/90 mmHg¡C§¿²G¤ÀªRµo²{500 mg/dL³J¥Õ§¿¡A¨H¾ýª«¤¤°ª­¿Ãè¤U¦³5-10 RBC¡A¨ÃµLRBC cast¡C¥Í¤ÆÀˬd¶EÂ_¬°µÇ¯f¯g­Ô¸s¡F¦å²M§K¬Ì¾ÇÀˬdµL¯S®íµo²{¡C¤U¦C¦óªÌ¤£¥¿½T¡H
A.³o¦~ÄÖªºµÇ¯f¯g­Ô¸s¥Ñ­ìµo©ÊµÇµ·²yª¢¤Þ°_ªºµo¥Í²v¡A¨Ì¦¸¬°¡Gminimal change disease (MCD)> focal segmental glomerulosclerosis (FSGS) > membranous glomerulopathy (MN)
B.¦³µÇ¯f¯g­Ô¸sªºFSGS¤ñ¨S¦³µÇ¯f¯g­Ô¸sªºFSGS¸û®e©ö¶i®i¬°¥½´ÁµÇ°IºÜ¡C¬ù¦³40%ªºFSGS¹ï©óÃþ©T¾JªvÀø¥i¥H±o¨ì§¹¥þ½w¸Ñ¡C¯f²z¤Á¤ùªºµ²ªG¨ÃµLªk¹w´ú­þ¨Ç¯f¤H¹ïÃþ©T¾J¦³®Ä¡C
C.³o­Ó¦~ÄÖªºMCD¹ïÃþ©T¾Jªº¤ÏÀ³¸û¤p«ÄªºMCD®t¡]¬ù75%¥i¥H½w¸Ñ¡^¡A¦ý¬O¦Aµoªº±¡§Î¸û¤Ö¡C¹ï©ó¸g±`¦Aµoªº¯f¤H¡AÀ³¦Ò¼{cyclophosphamide¡C
D.MNªº¯f¤H­Y¤£ªvÀø¡A¸g¹L4¦~¦³35%¯f¤H·|¶i®i¬°¥½´ÁµÇ°IºÜ¡C¹q¤lÅã·LÃ誺¯f²z¶EÂ_­Y¬°²ÄIII©MIV´Á¡A¹w«á¸û®t¡C
E.¦UºØµÇµ·²yª¢ªº¹w«á¤£¦P¡A¸g¹LÂå®vªº¸Ô²Ó¸Ñ»¡¡A¯f¤H¤´©Úµ´°µµÇŦ¤Á¤ù¡A¦]¦¹§^¤HµLªk³]©wªvÀø­pµeªvÀø¦¹¯f¤H¡C
 
(C) 3.¦³Ãöangiotensin-converting enzyme inhibitorsªºµÇŦ«OÅ@§@¥Î¡A¤U¦C¦óªÌ¦³»~¡H
A.¥i¥H­°§C¦åÀ£¡C
B.¥i¥H­°§CµÇµ·²y¤ºÀ£¤O¡C
C.­°§CµÇŦ¦å¬y¡C
D.§í¨î§]¾½²Ó­Mªº¬¡©Ê©M²¾¦æ¡C
E.­°§C³J¥Õ§¿¡C
 
(D) 4.¦³Ãö¿}§¿¯fµÇ¯fÅܪº±Ô­z¡A¤U¦C¦óªÌ¦³»~¡H
A.²Ä¤@«¬¿}§¿¯f¤H¸û²Ä¤G«¬ªÌ¦³¸û°ªªº¤ñ²vµo¥ÍµÇ¯fÅÜ¡C
B.¦b¥xÆW²Ä¤G«¬¿}§¿¯f¤H¦³¥|¦¨¥H¤W¥i¥Hµo²{¦³¤£¥¿±`ªº§¿³J¥Õ¡C
C.ÄY®æ±±¨î¦å¿}¥i¥H­°§C·L¥Õ³J¥Õ§¿¡]microalbuminuria¡^ªºµo¥Í¡C
D.²Ä¤@«¬¿}§¿¯f¤HÀ³¸Ó¦b¶EÂ_«á¡A´N­n¨C¦~¿zÀË·L¥Õ³J¥Õ§¿¡A¦Ó²Ä¤G«¬¯f¤H«h¦b¶EÂ_¿}§¿¯f¤­¦~«á¡A¨C¦~¿zÀˤ@¦¸¡C
E.µL½×²Ä¤@«¬©Î²Ä¤G«¬¡A¦åÀ£À³±±¨î¦b130/80 mmHg¥H¤U¡C
 
(C) 5.42·³¨k¯f¤H¦]ÀYµh¡Bµo¿N¡B¥H¤Î·NÃѵy¦³²V²c¬ù¤@¬P´Á¡C¯«¸g¾ÇÀˬd¨ÃµL¯S®í¤§³B¡A¦åÀ£¬°159/105 mmHg¡A²ä¤lµL»øµw±¡§Î¡C§¿²G¤ÀªR¦³++³J¥Õ§¿¡A+++¼ç¦å¡A¨H¾ýª«°ª­¿Ãè¤U¦³5-10 RBC¡A5-8 WBC¡C ¥Í¤ÆÀˬd¡GBUN 32 mg/dL¡Acreatinine 2.7 mg/dL¡AGOT 80 IU/L¡ALDH 1880 IU/L¡AHb 9.0 g/dL¡AWBC 11,000¡Aplatelet 49,000¡C¦å²G©Ù¤ù¦p¹Ï71©Ò¥Ü¡C¤U¦C¦³Ãö¦¹¯f¤Hªº±Ô­z¦óªÌ¦³»~¡H
A.¯f¤Hªºprothrombin time ©M partial thromboplastin timeÀ³¸Ó¥¿±`¡C
B.¯f¤H¦å¤¤ªºhaptoglobinÀ³¸Ó«Ü§C¡C
C.¥D­nªºªvÀø¤èªk¬Oµ¹¤©methylprednisolone¤j¾¯¶q¡A1g/day x 3 days¡C
D.§Ü¦å¤pªOªºÃĪ«ticlopidine·|¤Þ°_Ãþ¦üªº¯e¯f¡C
E.HIV·P¬Vªº¯f¤H¤]¥i¥H¦³Ãþ¦üªºªí²{¡C
 
(D) 6.63·³¨k©Ê¡A±w¦³ªÍÀù±µ¨ü¤Æ¾ÇªvÀø¤T¤Ñ«á¡C¦]·NÃѤ£²M³Q°e¦Ü«æ¶E³B¡C®a¤H§iª¾¯f¤H­¹¼¤¤£¦n¡A¦³äú¤ß¦ýµL¹Ã¦R¡F¨­ÅéÀˬd¡AÅé·Å36.8¢XC¡A¦åÀ£124/75 mmHg¡A¯ß·i78¡A©I§l18¡C¯f¤H°£¹ï®ÉªÅ¦³¿ù¶Ã¤Î¶ÝºÎ¥~¡A¨ä¥L¯«¸g¾ÇÀˬdµL²§±`¡F¤UªÏµL¤ô¸~¡C§¿²GÀˬd¥¿±`¡F§¿¯À´á18 mg/dL¡A§¿»Ä2.5 mg/dL¡AALT 20U/L¡A¦å¿}98 mg/dL¡C¦å²M¹q¸Ñ½è¡ANa+ 118¡AK+ 3.5¡ACl- 79¡ACa++ 2.4¡]¹q¸Ñ½è³æ¦ìmmol/L¡^¡C¹ï¦¹¯f¤H¤U¦C¦óªÌ±Ô­z¤£«ê·í¡H
A.¦³Ãö³o¦ì¯f¤Hªº¶EÂ_¡A´ú©w§¿²Gªºº¯³zÀ£¤ñ§¿²G¶uÂ÷¤l¿@«×¥i¾a¡C
B.¯f¤H¬O¤p²Ó­MªÍÀù¡]small cell lung cancer¡^¡A¥H¥Ø«e«Øijªº¤Æ¾ÇÀøªk©Ò¨Ï¥ÎªºÃĪ«¡AÀ³¸Ó¤£·|¤Þ°_³oºØ±¡ªp¡C
C.¯f¤Häú¤ß¥i¯à·|³y¦¨§C¶u¦å¯g¡A¥D­n¬Ovasopressin ¤Àªc¼W¥[¡C
D.¥¿½Tªº¶EÂ_¥²¶·´ú©w¦å¼ßªºvasopressin¿@«×¡C
E.³o¦ì¯f¤Hªº¸£À£À³¸Ó¬O¼W¥[ªº¡C
 
(C) 7.©Ó¤WÃD¸g¹LªvÀø«á¤T¤Ñ¡A¯f¤H¥X²{·NÃѧó¥[¼Ò½k¡Bconjugate gaze¥X²{»Ùê¡B¥|ªÏ»´Åõ¡]quadriparesis¡^¡A¹q¸£Â_¼hÄá¼v¦p¹Ï73 ¡C¤U¦C¦óªÌ±Ô­z¥¿½T¡H
A.¦pªG¦bÁB¥¿§C¶u¦å¯g®É¡A¦P®Éµ¹¤©10%mannitol¥i¥H¹w¨¾³oºØ¯fÅÜ¡C
B.³q±`³o¼Ëªº¯fÅܬO§C¶u¦å¯gÁB¥¿¤ÓºC©Ò­P¡C
C.¥H¤UªºªvÀø¥i¥H´î¤Ö©ÎÁקKµo¥Í¯fÅÜ¡G¥H3%NaClÀR¯ßÄéª`¡A³t«×¬O0.05 mL/Kg/min¥H¤U¡C
D.ÁB¥¿®É¥²¶·¨C¤p®É´ú©w¦å²M¶u¡A¤@ª½¨ì¦å²M¶u¹F¨ì135 mmol/L¬°¤î¡C
E.©ÎªÌ¦å²M¶u¼W¥[15 mmol/L¬°¤î¡C
 
(A) 8.¦³ÃöºC©ÊµÇŦ¯f¤H³h¦åªº±Ô­z¦óªÌ¥¿½T¡H
A.³o¨Ç¯f¤Hªº³h¦å¤j¦h¼Æ¬Onormocytic normochromic anemia¡C
B.­Y¯f¤H¦­´ÁµÇ¥\¯à¤£¥þ´Nµo¥Í³h¦å¡AÀ³¸Ó¦Ò¼{µÇµ·²yª¢¡C
C.³h¦åªº­ì¦]¥D­n¬O¬õ¦å²y¹Ø©RÁYµu¡A¨ä¦¸¬O¬õ¦å¥Í¦¨¯À¡]erythropoietein, EPO¡^´î¤Ö¡C
D.ÁB¥¿³o¨Ç¯f¤Hªº³h¦å¡A¨ä¥Ø¼Ð¬O¦å¤ñ®e¦b36-40%¡C
E.¹ïEPO²£¥Í§Ü©Êªº¥D­n­ì¦]¬O¡A¨­Åé²£¥Í§ÜEPO§ÜÅé¡A¦]¦¹«Øij¥Ö¤Uª`®g¡C
 
(C) 9.¤U¦C¨º¤@­Ó¯f¨Ò¤£²Å¦X©Ò¦C¤§°Ê¯ß¦å®ðÅé¤ÀªR©M¦å²M¹q¸Ñ½èªºÀˬdµ²ªG¡HpH 7.50, PO2 90 mmHg, PCO2 48 mmHg, HCO3- 34; Na+ 138, K+ 2.7, Cl- 89¡]¹q¸Ñ½èªº³æ¦ì¬Ommol/L¡^
A.40·³a¯f¤H¡A¦åÀ£160/108 mmHg¡A¦å¼ß¥Ö½èîÇଡþµÇ¯À¬¡©Ê¤ñ­È¬°80¡C
B.20·³b¤k©Ê¡A¨Ï¥Î§Q§¿¾¯´î­«¡C
C.50 ·³c¯f¤H­¹¹D¤â³N«áµ¹¤©¥þÀR¯ßÀç¾i¡C
D.45·³d¯f¤H¨C¤ÑÄZ­¹¶î¦³¥Û¦ÇªºÂb·}80Áû¡C
E.50·³e¯f¤H¶EÂ_¬°Gitelman syndrome¡C
 
(C) 10.©Ó¤WÃD¡A­Yµ¹¤©¥Í²z­¹ÆQ¤ô¡A­þ­Ó¯f¤Hªº¹q¸Ñ½è©M»ÄÆP°ÝÃD¥i¥HÀò±oÁB¥¿¡H
A.a + b + d
B.c + e
C.b + d
D.a + c + e
E.d + e
 
(B) 11.40·³¤k©Ê¯f¤H¦]°ª¦åÀ£±±¨î¤£©ö¨D¶E¡A¯f¤H¦åÀ£167/107 mmHg¡A¸¡³¡µLÂø­µ¡C§¿²G¤ÀªR¤ÀªR¥¿±`¡A¥Í¤ÆÀˬd¡ABUN 15 mg/dL¡ANa+ 145 mmol/L¡AK+ 3.0 mmol/L¡ACl- 100 mmol/L¡ACa++ 2.38 mmol/L¡C¯f¤H¥Ø«eªAÃĦ³¡Achlorothiazide 25 mg qd, atenolol 100 mg qd, amlodipine 10 mg qd¡C¯f¤H°±ÃĤ@¶g«á©â¦å¡A±oPRA (plasma rennin activity) ¬°10 ng /ml/hr¡]¥¿±`1-3.5)¡APAC (plasma aldosterone concentration)¬°35 ng/dL¡]¥¿±`12-28)¡C¤U­±Àˬd­þ­Ó¹ï©ó¶EÂ_¦¹¯f¤H¬O»Ý­nªº¡Ha. captopril test ¡]µ¹¤©50 mg captopril«á´úPRA©MPAC¡^b. saline infusion test ¡]¥|¤p®É¤ºµ¹¤©0.9% saline 2L«á´úPRA©MPAC¡^c. Postural change test¡]¦­¤W¤CÂI¥H¤Î¨«°Ê«á¤T¤p®É¦U´úPRA©MPAC¡^d. µÇ¤W¸¢¹q¸£Â_¼hÄá¼ve. captopril radionuclide renal scan
A.b + d
B.a + e
C.a + c + d
D.b + c + d
E.a + b + c + d + e
 
(D) 12.51·³¨k©Ê¡A¦³³J¥Õ§¿¤G¦~¤§¤[¡A¥­±`¤£ªAßÓ¡A¤T¤ë¥÷¦å¤¤¦Ù»ÄÓþ¡]creatinine¡^¬° 1.6 mg/dl¡A¥|¤ë¥÷¬° 2.5 mg/dl¡A¤»¤ë¥÷¬° 4.0 mg/dl¡A¤C¤ë¥÷¬° 5.3 mg/dl¡A§A¹w´Á¨äµÇ¬ï¨ë¯f²zÅܤƦ³¦ó¯SÂI¡]§Y¶EÂ_¤W¤§¯S¼x¡^¡H
A.µÇ¤pºÞÃa¦º¡]tubular necrosis¡^¡C
B.µÇ¤p²yµw¤Æ¡]glomerular sclerosis¡^¡C
C.µÇ¤p¦åºÞÃa¦º¡]vessel necrosis¡^¡C
D.µÇ¤p²y·s¤ë§Î¦¨¡]glomerular crescent formation¡^¡C
E.µÇ¶¡½èÅÖºû¤Æ¡]interstitial fibrosis¡^
 
(E) 13.40·³¨k©Ê¡A³Q¶EÂ_¬°Henoch-Schonlein purpura¡A§A¹w´Á¨ä¯f²z¤Á¤ù¬°¨º¤@ºØ¯fÅÜ¡H
A.½¤©ÊµÇ¯fÅÜ¡C
B.Ig M µÇ¯fÅÜ¡C
C.·¥·LÅܤƫ¬¯fÅÜ¡C
D.Äjº©¼W¥Í«¬µÇ¤p²yµÇª¢¡C
E.Ig A µÇ¯fÅÜ¡C
 
(C) 14.52·³¨k©Ê¡A¨ä¦å¶u¿@«×¬°110 mEq/L¡A¦å¼ßº¯³zÀ£¬°258 mOsm/L¡Aµû¦ô°_¨Ó¡AÅé²G®e¿n¬°¹L³Ñ¡]volume excess¡^ª¬ºA¡A¤U¦C¨º¤@¶µ¤£¦X¦¹±¡ªp¡H
A.¨xµw¤Æ¡C
B.¤ßŦ°IºÜ¡C
C.§Ü§Q§¿²üº¸»X¤Àªc¤£·í¯g­Ô¸s¡]SIADH¡^¡C
D.µÇ¯f¯g­Ô¸s¡]nephrotic syndrome¡^¡C
E.¥F§¿©Ê«æ©ÊµÇ°IºÜ¯f¤H³Ü¤ô¹L¦h¡C
 
(C) 15.35·³¤k©Ê¡A¦b«æ¶E³B³Qµo²{¦å¹[ 7.5 mEq/L¡A¨ä¤ß¹q¹Ï¥X²{°ªªºTªi¡AQRS©µªø¡C§A²Ä¤@¨B­nµ¹ªº³B²z¡]¤]¬Oµo¥Í®Ä²v³Ì§Ö¡^¬O¨º¤@¶µ¡H
A.µ¹¤©insulin¥[¸²µå¿}ÀR¯ß¿éª`¡C
B.µ¹ £]2- ¥æ·P¯«¸g«P¶i¾¯¡]£]2- adrenergic agonists¡^¡C
C.µ¹¤© calcium gluconate¡C
D.µ¹§Q§¿¾¯¡C
E.µ¹Â÷¤l¥æ´«¾¯¡]cation exchang resins¡^¡C
 
(E) 16.48·³¨k©Ê¡A¦å¶t 2.65 mmol/L¡]¥¿±` 2-2.6 mmol/L¡^¨ä¦å²M¥Õ³J¥Õ¬° 2.7 g/dl¡A§A¦bŲ§O¶EÂ_®É¡A¤£¥²¦Ò¼{¨º¤@ºØ±¡§Î¡H
A.´c©Ê¸~½F¡C
B.¥Òª¬¸¢¾÷¯à¤®¶i¯g¡C
C.Sarcoidosis¡C
D.¨Ï¥Îthiazide§Q§¿¾¯¡C
E.«æ©Ê¯ØŦª¢¡C
 
(B) 17.§A¬Ý¨ì¦³¤@¦ì¯f¤H¦í°|¤¤¥Lªº¥DªvÂå®v¦b¹ï¥LÀR¯ßª`®gNaHCO3¡A¦Ó¥B¦b´ú¶q¦å¤¤HOO3-¿@«×¡A§¿ªºpH­È¥H¤ÎHCO3-±Æªn²v¡]fractional excretion of HCO3-¡^¡A§A·Q¦¹¯f¤H­ì¨Óªº»ÄÆP¥¢¿ÅÀ³¬°¨º¤@ºØ¡H
A.©I§l©ÊÆP¤¤¬r¡]respiratory alkalosis¡^¡C
B.¥NÁ©ʻĤ¤¬r¡]metabolic acidosis¡^¡C
C.©I§l©Ê»Ä¤¤¬r¡]respiratory acidosis¡^¡C
D.¥NÁ©ÊÆP¤¤¬r¡]metabolic alkalosis¡^¡C
E.µL»ÄÆP¥¢¿Å²{¶H¡C
 
(B) 18.¦ñ¦³ºC©ÊµÇ¯f¤§°ª¦åÀ£¯f¤H¡A­Y¯f¤H¦³³J¥Õ§¿¡A¨Ï¥Î¨º¤@ºØ­°À£¾¯¹ïµÇ¯f¤§´c¤Æ¥i¥H´î½w¡H
A.¶tÂ÷¤lªýÂ_¾¯¡C
B.¦åºÞ±i¤O¯ÀÂà´«úC§í¨î¾¯¡]ACE inhibitor¡^¡C
C.§Q§¿¾¯¡C
D.¥æ·P¯«¸gªýÂ_¾¯¡]sympatholytic agents¡^¡C
E.ª½±µ§@¥Î¦åºÞÂX±i¾¯¡]direct-acting vasodilators)¡C
 
(C) 19.¦¬¶°24¤p®É§¿´ú¶q³J¥Õ±Æªn¬J³Â·Ð¤S¤£©ö·Ç½T¡A­Y¥HÀH¾÷¤@¦¸§¿¤¤³J¥Õ¡]mg/dl¡^¤ñ¦Ù»ÄÓþ¡]creatinine¡^¡]mg/dl¡^¤§¤ñ­È¥Nªí¤ñ¸û¤è«K¡A¦h¤Ö¤ñ­È¥H¤W¦Ò¼{Nephrotic range¤§³J¥Õ§¿¡H
A.1¥H¤W¡C
B.2¥H¤W¡C
C.3¥H¤W¡C
D.0.3¥H¤W¡C
E.0.1¥H¤W¡C
 
(B) 20.48·³¤k©Ê¡A¶}¹L¸¡³¡¤â³N¤T¦¸¡A²{¦]ºC©Ê§¿¬r¯g±N±µ¨ü³zªRªvÀø¡A§A¿ï¾Ü¨º¤@ºØÀøªk¡H
A.³sÄò¥i¬¡°Ê©Ê¸¡½¤³zªR¡]CAPD ¡^¡C
B.¦å²G³zªR¡]hemodialysis¡^¡C
C.¶¡·²©Ê¸¡½¤³zªR¡]intermittent PD¡^¡C
D.¦å²GÄé¬y¡]hemoperfusion¡^¡C
E.¦Û°Ê¤Æ¸¡½¤³zªR¡]automatic PD¡^¡C
 
(C) 21.50·³¨k©Ê¦í°|¯f¤H¡A¦å¹[¿@«×¬° 2.5 mEq/L¡A¤U¦C¨º¨Ç§A­n¦C¤J¦Ò¼{¡Ha. ÄY­«µÇ°IºÜb. ¥NÁ©ÊÆP¤¤¬r¡]metabolic alkalosis¡^c. µÇ¤W¸¢¥\¯à¤£¨¬¡]adrenl insufficiency¡^d. ¨Ï¥Î£]2-¥æ·P¯«¸g«P¶i¾¯¡]£]2- adrenergic agonists¡^e. ¥Î§Q§¿¾¯ f. ¨Ï¥Î¦åºÞ±i¤O¯ÀÂà´«úC§í¨î¾¯¡]ACE inhibitor¡^
A.a + b + c
B.a + c + f
C.b + d + e
D.b + c + d
E.c + d + f
 
(D) 22.¤U¦C¨º¨Ç±¡ªp·|µo¥Í¥NÁ©ʻĤ¤¬r¡]metobolic acidosis¡^a. ¹Ã¦Rb. ¸¡Âmc. ¨Ï¥Î¥Ò¾J¡]methanol¡^d. µÇ°IºÜe. µÇ°Ê¯ß¯U¯¶f. ¨Ï¥Î§Q§¿¾¯g. ¹[¯Ê¥Fh. °§¾j¡]starvation¡^
A.a + b + d + e
B.b + d + e + g
C.c + d + e + f
D.b + c + d + h
E.b + d + e + g
 


< ¤E¤Q¤T¦~«×¸ÕÃD¥Ø¿ý >